AzTrials
AzTrials

Pulmonary HypertensionNCT04224012

Effect of Exercise and Respiratory Therapy on Right Ventricular Function in Severe Pulmonary Hypertension

A study testing Exercise and respiratory therapy in people with Pulmonary Hypertension, run by Heidelberg University at 1 site in Germany.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Chronic pulmonary hypertension (PH) is associated with impaired exercise capacity, quality of life and right ventricular function.The disease is characterized by an increase of pulmonary vascular resistance and pulmonary arterial pressure, leading to right heart insufficiency. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pulmonary Hypertension
What is being tested?
Exercise and respiratory therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
96 participants
Where
1 siteGermany
Study dates
Aug 2015to Aug 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Consent form
  • Men and women >18 years
  • Symptomatic PH (WHO-FC II-IV) invasive diagnostis with right heart catheterization: mPAP >25mmHg and a stable optimized treatment for at least 2 month
  • Ptients who are able to understand and agree to participate in the study

Who cannot join

  • Pregnancy or breast feeding
  • Variation in the medication during the last 2 months
  • Patients with signs of right heart decompensation
  • Major walking problems
  • Unclear diagnosis
  • No invasive clarification of the PH
Show all 9Show fewer
  • Acute illness, infections and fever
  • Grave lung disease with FEV1 <50% or TLC <70% from target
  • Further conclusion criteria are followed: acrive myokarditis, unstable angina pectoris, movement induced venr´tricular rhythmdisturbance, decompensation of the right hart insufficiency, meaningful heartvitien, hyperthrophic obstructive cardiomyopathie or a high grade reduced left ventricular pumpu function

Trial locations and contacts

1 site in 1 country.

Germany1 site, 1 recruiting
  • Centre for Pulmonary Hypertension at the Thoraxklinik, Heidelberg University Hospital

    Heidelberg, 69126

    Ekkehard Grünig, MD, +496221396 ext. 8053, ekkehard.gruenig@med.uni-heidelberg.de

    Ekkehard Grünig, MD

    Recruiting

Other trials in Germany

About this study

Chronic pulmonary hypertension (PH) is associated with impaired exercise capacity, quality of life and right ventricular function.The disease is characterized by an increase of pulmonary vascular resistance and pulmonary arterial pressure, leading to right heart insufficiency. In later stages of the disease, the right heart is not able to further increase right ventricular contractility (cardiac index) during exercise. Within the last decade, new disease-targeted medical therapies have been approved for treatment of pulmonary arterial hypertension (PAH). Sequential and upfront combinations of these agents have shown to further improve symptoms, 6-minute walking distance (6-MWD) and hemodynamics in PAH patients.

Previous training studies have suggested that exercise training as add-on to medical treatment is highly effective improving exercise capacity, quality of life and symptoms. Prospective studies with a 24±12 months follow-up period suggested that exercise training may also improve the rate of clinical worsening events as the need for hospitalization, additional PH-medication, lung-transplantation and death.

Read more

There is also first data that exercise training may have a positive impact on the right ventricular function.

This randomised controlled study aims to assess whether exercise training

Read the detailed description

The aim of this prospective, randomized, controlled study in patients with pulmonary hypertension, who are under stable optimized treatment for at least 2 months, is to examine the effect of an additional exercise and respiratory therapy on the right heart function.

The primary endpoint of this study is the right heart function, measured by cardiac index during exercise invasively determined by right heart catheterization. More hemodynamic parameters for the determination of the right heart function as well as clinical and molecular parameters are relevant to record the physiological effect of the training. The molecular parameters are composed of laboratory parameter and inflammatory parameter as well as genetic analyses, measurements of epigenetic changes measured by microRNA Expressions and DNA-methylation and imunohistochemical measurements of the quadriceps musculature.

The study parameters will be assessed in the patient's routine examinations. Clinical parameters comprise of hemodynamic assessment of pulmonary arterial pressure during exercise, pump function of left and right ventricle, and further echocardiographic parameters. Improvement of exercise capacity will be measured by the change of six-minute walking distance, the breathing economics, the world health organization functional class (WHO functional class), peak oxygen consumption and blood gas analysis. The quality of life will be assessedwith the SF-36 questionnaire.Data for survival analysis will be gained by structured phone interviews . The safety of the training is warranted by long-term, rest- and stress-ECG, safety laboratory, systemic blood pressure, heart frequency, oxygen saturation and occurrence of adverse events. In addition to the routine examinations at baseline and after 15 weeks, a right heart catheterization will be performed.

Patients will be examined in the Thoraxklinik Heidelberg. Patients of the training group will take part in a specific, 3-week inpatient training program at the rehabilitation center Königstuhl Heidelberg right after the baseline examination. The training program consists of exercise and respiratory therapy as well as a mental gait training. Respiratory therapy will be performed 5 times/week for 30 minutes. Furthermore, 15-25 minutes low dosed interval training on a bicycle ergometer, dumbbell training of particular muscle groups with low weights and supervised walks on ground-level will be scheduled 5-7 times/week. Three- to five times a week a "mental gait training" is conducted to estimate the patient's individual physical abilities and limitations. The heart rate during exerciseand the intensity of the training will be closely monitored and individually adjusted. After three weeks of in-hospital rehabilitation the patients are asked to continue the training for twelve further weeks at home. All patients will be examined before the training program, at the end of the in-hospital phase after three weeks and after 15 weeks. Patients of the control group will continue with their lifestyle without individual training prescriptions. After having participated in the study, patients of the control group will also be offered to take part in the training program.

The control examinations cover the medical history, WHO functional class, physical examination, ECG, echocardiography at rest and during exercise, spiroergometry, quality of life, blood-gas analysis, lung function, 6-minute walking distance, oxygen saturation, blood pressure and heart rate, laboratory tests. An optional magnet resonance imaging at the beginning and after three months may also be conducted. At baseline, an optional genetic assessment will be performed; and at the beginning, after three and 15 weeks the expression levels of micro RNA and methylation of the DNA will be assessed. A biopsy of the quadriceps musculature will optionally be carried out at baseline and after 15 weeks. Medication will remain stable throughout the study.

Being tested
Exercise and respiratory therapy
Medical subject headings
Hypertension, Pulmonary

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Exercise and respiratory therapyOther

    Three weeks in-Hospital Rehabilitation program with continuation of exercise Training at home

Study groups in NCT04224012
Study groupRoleWhat they receive
Conventional therapy group (control group)No interventionpatients of the control Group receive usual care
Interventional group (training group)ExperimentalSpecialized exercise and respiratory therapy for patients with pulmonary hypertension
Receives: Other: Exercise and respiratory therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cardiac index during exercise, right heart catheter

    measured by right heart catheterisation; Training vs. control group

    Measured: Change form baseline to final assessment after 15 weeks

Secondary outcomes (19)
  1. Cardiac index at rest, right heart catheter

    right heart catheterization cardiac index at rest

    Measured: Change form baseline to final assessment after 15 weeks

  2. Pulmonary vascular resistance at rest, right heart catheter

    right heart catheterization pulmonary vascular resistance at rest

    Measured: Change form baseline to final assessment after 15 weeks

  3. 6-minute Walking distance

    Physical exercise capacity, Walking distance in metres

    Measured: Change form baseline to final assessment after 15 weeks

  4. Peak oxygen consumption, cardiopulmonary exercise testing

    cardiopulmonary exercise testing

    Measured: Change form baseline to final assessment after 15 weeks

  5. Peak Workload in Watts, achieved during cardiopulmonary exercise testing

    cardiopulmonary exercise testing

    Measured: Change form baseline to final assessment after 15 weeks

  6. Peak respiratory equivalent during cardiopulmonary exercise testing

    cardiopulmonary exercise testing

    Measured: Change form baseline to final assessment after 15 weeks

  7. Epigenetic changes of micro RNA

    Epigenetic changes of the microRNA and the state of methylization (muscle biopsy of the quadrizeps muscuation and peripheral blood)

    Measured: Change form baseline to final assessment after 15 weeks

  8. right atrial area, assessed by echocardiography

    Echocardiography

    Measured: Change form baseline to final assessment after 15 weeks

  9. right ventricular area, assessed by echocardiography

    Echocardiography

    Measured: Change form baseline to final assessment after 15 weeks

  10. right ventricular pump function, qualitative during echocardiography

    Echocardiography

    Measured: Change form baseline to final assessment after 15 weeks

  11. tricuspid annular plane systolic excursion, echocardiography

    Echocardiography

    Measured: Change form baseline to final assessment after 15 weeks

  12. Physical Summation score, SF-36

    Quality of life by short form health Survey 36 (SF-36); values from 0-100 (higher value = better outcome)

    Measured: Change form baseline to final assessment after 15 weeks

  13. Mental Summation score, SF-36

    Quality of life by short form health Survey 36 (SF-36)values from 0-100 (higher value = better outcome)

    Measured: Change form baseline to final assessment after 15 weeks

  14. World Health Organization functional class

    symptoms of pulmonary hypertension

    Measured: Change form baseline to final assessment after 15 weeks

  15. Laboratory: Levels of N-terminal pro brain natriuretic peptide (NT-proBNP)

    marker of the right heart strain

    Measured: Change form baseline to final assessment after 15 weeks

  16. Oxygen Saturation, blood gas analysis

    Blood gas analysis

    Measured: Change form baseline to final assessment after 15 weeks

  17. Right heart size, assessed by magnetic resonance tomography

    magnetic resonance tomography

    Measured: Change form baseline to final assessment after 15 weeks

  18. Right heart function, qualitative, assessed by magnetic resonance tomography

    magnetic resonance tomography

    Measured: Change form baseline to final assessment after 15 weeks

  19. Clinical worsening, frequency of clinical worsening and adverse Events during the study period

    frequency of clinical worsening events

    Measured: assessed form baseline to final assessment after 15 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jan 2020
  2. Study startAug 2015
  3. Primary completionAug 2024 (estimated)
  4. Study completionAug 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
96 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04224012
Sponsor's protocol ID
TRAIN-01
Status last verified
Jul 2022
First submitted
19 Dec 2019
Last updated
14 Jul 2022
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Exercise and respiratory therapy in people with Pulmonary Hypertension, run by Heidelberg University at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 14 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cardiac index during exercise, right heart catheter (time frame: Change form baseline to final assessment after 15 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in